PointState Capital’s DexCom DXCM Stock Holding History

PointState Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,244,000	Closed	-$18.6M	–	140
2016 Q4	$18.6M	Buy	+1,244,000	New	+$22M	0.27%	74

Other funds holding DXCM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PointState Capital's DXCM Position: Q1 2017 in Review

PointState Capital sold out of DexCom (DXCM) in Q1 2017, closing a stake of 1,244,000 shares — an estimated $18.6M sold.

PointState Capital first reported a position in DXCM in Q4 2016 and held it in 1 quarter. The position peaked at $18.6M in Q4 2016. 321 funds tracked by Wall St. Rank hold DXCM as of Q1 2017.

PointState Capital reported no remaining DexCom position as of Q1 2017 after selling out during the quarter.
PointState Capital sold 1,244,000 DexCom shares in Q1 2017, an estimated $18.6M.
PointState Capital first reported a position in DexCom in Q4 2016 and held it in 1 quarter.
PointState Capital's DexCom position peaked at $18.6M in Q4 2016.
321 funds tracked by Wall St. Rank held DexCom as of Q1 2017.

Based on PointState Capital's 13F filing for Q1 2017, filed 15 May 2017.